Transgene Expression in Cultured Cells Using Unpurified Recombinant Adeno-Associated Viral Vectors
October 20th, 2023
Recombinant adeno-associated virus (rAAV) is widely used for clinical and preclinical gene delivery. An underappreciated use for rAAVs is the robust transduction of cultured cells without the need for purification. For researchers new to rAAV, we provide a protocol for transgene cassette cloning, crude vector production, and cell culture transduction.
Gene therapy uses a viral capsid to introduce DNA into cells, and then the cells process that DNA through mechanisms that aren't fully understood. By studying how the cell processes AAV delivered DNA, we hope to improve safety, efficacy and longevity of AAV gene therapies. Studying AAV DNA processing at the tissue or organism level was quite difficult.
And while we were developing cell culture transduction protocols for AAV visualization via super resolution microscopy, we found that the simplicity of producing and using unpurified AAV preparations in cell culture is not well known. This straightforward method for transient expression can be advantageous for researchers in numerous fields. Creating crude AAV preparations is quite simple, and they have a long shelf life F4C, allowing them to be used in numerous experiments.
Applying them is simple, making them a time and cost-effective alternative to standard transfection reagents. Often AAV crude preparations are more efficient and less toxic than transfection. Vectrology has two arms, production and transduction, and both are entirely dependent on host cellular machinery.
Our future research aims to identify the cellular machinery involved in these processes and ways to manipulate them so that we can improve production and transduction efficiency. Understanding the basic biology underpinning both arms of vectrology is vital for the success of gene therapies.
Overview
This study focuses on the use of recombinant adeno-associated virus (rAAV) for gene delivery, utilizing viral capsids to introduce DNA into cells. The simplicity and efficiency of producing unpurified rAAV preparations for cell transduction are emphasized, providing a cost-effective alternative to conventional transfection methods.
Key Study Components
Research Area
- Gene therapy
- Cell transduction
- Viral vector technology
Background
- Current methodologies in AAV gene therapy
- Challenges in studying AAV DNA processing
- The need for efficient and less toxic transfection alternatives
Methods Used
- Protocol for transgene cassette cloning and crude vector production
- Use of cultured cells
- Transduction of cells without purification
Main Results
- Unpurified AAV preparations show robust transduction efficiency
- These preparations offer long shelf-life and ease of use
- Crude AAVs can be more effective and less toxic compared to traditional transfection methods
Conclusions
- This study demonstrates a simplified approach to gene delivery using rAAVs
- It highlights the potential to improve gene therapy methodologies across various fields of research
